## Life Sciences: San Francisco Bay Area

Powered by Savills Research & Data Services

# savills

#### **Market Highlights**

- ArsenalBio has raised \$325.0 million in Series C funding to accelerate the development of its lead programs, which focus on therapeutic candidates for treating solid tumor cancers.
- Longfellow's ground lease in Emeryville for the 750,000square-foot (sf) Atrium Labs development was terminated after allegations of \$1,006,250 in unpaid rent.

The UC Regents have approved the construction of UCSF's new Life Sciences Building, which will feature a proton therapy center and a cutting-edge life sciences incubator. The facility is slated to open in 2029.

#### **Major Developments Under Construction**





- SF: 364,000
- North building in 1.2 million square foot (msf) campus
- Delivery: Q2 2025
- Developer: Build Group Inc.



#### 580 Dubuque Avenue

- SF: 339,993Delivery: Q1
- 2025
   Developer:
- Developer: IQHQ



#### 1350 Adams Court


- SF: 255,000Delivery: Q1
- 2025
   Developer:
  Tarlton
  Properties



#### 200 Twin Dolphin Drive

- SF: 234,000
- Delivery: Q1 2025
- Developer: Trammell Crow Company

#### **Life Sciences Related VC Funding**



Companies	Deal Size	Deal Type
ArsenalBio	\$325.0M	Series C
Caresyntax	\$310.0M	Series C
Imperative Care	\$150.0M	Series E
Nura Bio	\$141.0M	Series A
Moximed	\$91.0M	Series D

#### **Notable Leases**



#### Natera

201 Industrial Rd 136,258 sf Q3 2024



#### Cepheid

904 E Caribbean Dr 80,546 sf 03 2024



#### Nevro Corp

1800 Bridge Pkwy 52,202 sf 03 2024



#### Vaxcyte

825 Industrial Rd 38,200 sf Q3 2024



### Attovia

1091 industrial Rd 30,000 sf 03 2024